Triple-negative breast cancer

There are 125 papers on triple-negative breast cancer in aging research: 4 trials and 58 observational studies in people, 28 in animals, 8 in cells, 17 reviews. The newest story, Oct 23, 2026: “Older women with triple-negative breast cancer had worse survival”.

Disease

125 papers study it6 more mention it42 findings

7 new papers in 30 daysSee all 131 papers on triple-negative breast cancer

At a glance

Triple-negative breast cancer is associated with lower Phenotypic Age Acceleration ten years after diagnosis than hormone receptor–positive/HER2-negative breast cancer in a human study, while other studies find no clear links with epigenetic age or telomere length. Older patients have more mutated Cancer Gene Census genes than younger patients; human cohorts also link obesity with this cancer in Black women.

42 findings in 31 papers from 2017 to 2026, 7 of them since April 2026

“we did not find any causal effect of TNBC or BRCA1-mutated TNBC on TL, nor did any other breast cancer subtypes have an effect on TL”
Causal Association between Genetically Predicted Telomere Length and Breast Cancer Risk: A Bidirectional Two-sample Mendelian Randomization StudyCurrent Cancer Therapy Reviews2026doi:10.2174/0115733947405850260331190530
  • Human trial4
  • Humans58
  • Animals27
  • Model organisms1
  • Cells8
  • In silico8

Interventions

3

Venetoclax

downin mice1

1 study
  1. Venetoclax decreases triple-negative breast cancer in mice following talazoparib and radiotherapy.

    Animalsfollowing talazoparib and radiotherapy

More on Venetoclax

Camptothecin + metformin + GW280264X

downin mice1

1 study
  1. Camptothecin + metformin + GW280264X inhibits triple-negative breast cancer in vivo TNBC model.

    Animalsin vivo TNBC model

More on Camptothecin + metformin + GW280264X

Caloric restriction

downin mice1

1 study
  1. Caloric restriction decreases triple-negative breast cancer in a TNBC mouse model receiving chemotherapy.

    Animalsin a TNBC mouse model receiving chemotherapy

More on Caloric restriction

Effects

5

Telomere length

no changein humans1

1 study
  1. Triple-negative breast cancer was not clearly linked with telomere length in humans.

    Humans

More on Telomere length

BRCA1 and BRCA2 expression

downin humans1

1 study
  1. Triple-negative breast cancer is linked with lower BRCA1 and BRCA2 expression in humans (compared with other subtypes and age groups).

    Humanscompared with other subtypes and age groupsbreastfemalesn = 102

More on BRCA1 and BRCA2 expression

FAM3B expression

downin humans1

1 study
  1. Triple-negative breast cancer is linked with lower FAM3B expression in humans.

    Humansbreast

More on FAM3B expression

Mutated Cancer Gene Census genes per sample

upin humans1

1 study
  1. Triple-negative breast cancer is linked with higher mutated Cancer Gene Census genes per sample in humans (elderly (≥75) versus young (≤40) patients) (median 6 vs 3 mutated CGCs per sample).

    Humanselderly (≥75) versus young (≤40) patientsn = 109

More on Mutated Cancer Gene Census genes per sample

Epigenetic age

no changein humans1

1 study
  1. Triple-negative breast cancer was not clearly linked with epigenetic age in humans.

    Humansbreastfemales

More on Epigenetic age

Upstream

2

BioAgeAccel

mediatesin silico1

1 study
  1. BioAgeAccel mediates triple-negative breast cancer in silico (causal effect of type 2 diabetes mellitus and triple-negative breast cancer) (mediating effect -0.010, 95% CI -0.020 to -0.001).

    In silicocausal effect of type 2 diabetes mellitus and triple-negative breast cancer

More on BioAgeAccel

Dietary inflammatory index

no changein humans1

1 study
  1. Dietary inflammatory index was not clearly linked with triple-negative breast cancer in humans.

    Humansfemales

More on Dietary inflammatory index

Associations

31

Obesity

upin humans2HR 2.77

2 studies
  1. Obesity is associated with triple-negative breast cancer in humans (Black women; BMI >30 kg/m2) (HR 2.77, 95% CI 1.05–7.30).

    HumansBlack women; BMI >30 kg/m2breastMean follow-up of 5.8 yearsfemalesn = 25,013

  2. Obesity is associated with triple-negative breast cancer in humans.

    Review

More on Obesity

Interval breast cancer diagnosed within 1–12 months

upin humans1OR 2.08

1 study
  1. Interval breast cancer diagnosed within 1–12 months are associated with triple-negative breast cancer in humans (compared with interval breast cancer diagnosed at 13–24 months) (OR 2.08, 95% CI 1.26–3.39).

    Humanscompared with interval breast cancer diagnosed at 13–24 monthsbreastfemalesn = 2,122

More on Interval breast cancer diagnosed within 1–12 months

Mean asymptomatic time

downin silico1

1 study
  1. Triple-negative breast cancer is associated with mean asymptomatic time in silico (4.5 vs 7.6 vs 11.8 years).

    In silico

Tumor mean doubling time

downin silico1

1 study
  1. Triple-negative breast cancer is associated with tumor mean doubling time in silico (126 days vs 203 days vs 332 days).

    In silico

Proportion of interval cancers

upin silico1

1 study
  1. Triple-negative breast cancer is associated with proportion of interval cancers in silico (regular screening attenders) (48.9% vs 32.3% vs 22.0%).

    In silicoregular screening attenders

MAP2K2

mixedin silico1

1 study
  1. MAP2K2 is associated with triple-negative breast cancer in silico (compared with overall breast cancer, with opposite association signs).

    In silicocompared with overall breast cancer, with opposite association signs

More on MAP2K2

Autophagy

mixedin silico1

1 study
  1. Autophagy is associated with triple-negative breast cancer in silico (Stouffer Z −8.98; bootstrap 95% CI −14.78 to −3.09; permutation p = .0022; pathway FDR = .022).

    In silicotissue-combined S-PrediXcan scores, Stouffer enrichment of 35 NMN-responsive gene-derived pathways

More on Autophagy

Estrogen

upin humans1

1 study
  1. Estrogen is linked with a higher risk of triple-negative breast cancer in humans (highest vs. low CLEEE tertile) (aOR 1.90, 95% CI 1.12-3.26).

    Humanshighest vs. low CLEEE tertile

More on Estrogen

Oxidative phosphorylation

upin silico1

1 study
  1. Oxidative phosphorylation is associated with triple-negative breast cancer in silico (positive trends only; TWAS of GWAS summary statistics).

    In silicopositive trends only; TWAS of GWAS summary statisticsn = 133,384

More on Oxidative phosphorylation

Apoptosis

upin silico1

1 study
  1. Apoptosis is associated with triple-negative breast cancer in silico (enrichment restricted to triple-negative disease; TWAS of GWAS summary statistics) (GOCC BCL 2 FAMILY PROTEIN COMPLEX ALL meta-Z +6.40, permutation P 0.034).

    In silicoenrichment restricted to triple-negative disease; TWAS of GWAS summary statisticsn = 133,384

More on Apoptosis

All 31

Trial sponsors

Funding

10 grants since 2017

National Cancer Institute$4.5MDepartment of Health, Australian GovernmentA$652KMedical Research Future FundA$652K

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    An in silico study associates triple-negative breast cancer with interval cancer proportions among regular screening attenders, tumor doubling time and asymptomatic duration. Reviews link it to obesity in humans and to BRCA1 in females.

  2. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 10Feb 2026: 7Mar 2026: 8Apr 2026: 3May 2026: 2Jun 2026: 1Jul 2026: 2Aug 2026: 4Sep 2026: 3Oct 2026: 4Nov 2026: 348 papers in 12 months
Aging Clinical and Experimental Research

Older women with triple-negative breast cancer had worse survival

Five-year overall survival was 56.0% in women aged 70 or older, versus 83.0% in those aged 46–69.Five-year overall survival was 56.0% in women aged 70 or older, versus 83.0% in those aged 46–69.

Cohort · 289 peopleTriple-negative breast cancer

See all 131 papers on triple-negative breast cancer